Indo-Bangla Pharmaceuticals Limited (DSE:IBP)
Bangladesh · Delayed Price · Currency is BDT 17.20
0.00 (0.00%)
At close: Jul 6, 2026
DSE:IBP Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jul '22 Jul 1, 2022 | Jul '21 Jul 1, 2021 |
| 242.1 | 184.18 | 176.64 | 374.48 | 484.68 | 782.24 | |
Revenue Growth (YoY) | 165.76% | 4.27% | -52.83% | -22.74% | -38.04% | -9.68% |
Cost of Revenue | 193.69 | 163.15 | 156.79 | 277.92 | 337.75 | 469.3 |
Gross Profit | 48.41 | 21.02 | 19.85 | 96.56 | 146.93 | 312.94 |
Selling, General & Admin | 52.25 | 45.07 | 43.61 | 67.88 | 111.13 | 139.64 |
Other Operating Expenses | 0.02 | 0.02 | - | - | - | - |
Operating Expenses | 52.27 | 45.08 | 43.61 | 67.88 | 111.13 | 139.64 |
Operating Income | -3.86 | -24.06 | -23.76 | 28.68 | 35.8 | 173.3 |
Interest Expense | -0.55 | -1.87 | -4.4 | -5.23 | -4.88 | -3.81 |
Other Non Operating Income (Expenses) | 0.03 | 0.1 | 0.25 | 0.42 | 0.8 | 0.63 |
EBT Excluding Unusual Items | -4.37 | -25.83 | -27.91 | 23.87 | 31.72 | 170.11 |
Gain (Loss) on Sale of Assets | - | - | - | 0.7 | - | -0.77 |
Pretax Income | -4.37 | -25.83 | -27.91 | 24.57 | 31.72 | 169.34 |
Income Tax Expense | 10.02 | 11 | 13.07 | 16.17 | 6.55 | 34.62 |
Net Income | -14.39 | -36.83 | -40.98 | 8.41 | 25.17 | 134.73 |
Net Income to Common | -14.39 | -36.83 | -40.98 | 8.41 | 25.17 | 134.73 |
Net Income Growth | - | - | - | -66.60% | -81.31% | -13.77% |
Shares Outstanding (Basic) | 116 | 116 | 116 | 116 | 116 | 114 |
Shares Outstanding (Diluted) | 116 | 116 | 116 | 116 | 116 | 114 |
Shares Change (YoY) | -2.37% | - | - | - | 2.17% | - |
EPS (Basic) | -0.12 | -0.32 | -0.35 | 0.07 | 0.22 | 1.18 |
EPS (Diluted) | -0.12 | -0.32 | -0.35 | 0.07 | 0.22 | 1.18 |
EPS Growth | - | - | - | -66.60% | -81.71% | -13.77% |
Free Cash Flow | 56.82 | 57.89 | 23.64 | 42.92 | 47.6 | -49.39 |
Free Cash Flow Per Share | 0.49 | 0.50 | 0.20 | 0.37 | 0.41 | -0.43 |
Dividend Per Share | 0.015 | 0.015 | 0.010 | - | 0.100 | 0.400 |
Dividend Growth | 50.00% | 50.00% | - | - | -75.00% | - |
Gross Margin | 19.99% | 11.42% | 11.24% | 25.79% | 30.31% | 40.01% |
Operating Margin | -1.59% | -13.06% | -13.45% | 7.66% | 7.39% | 22.15% |
Profit Margin | -5.94% | -20.00% | -23.20% | 2.25% | 5.19% | 17.22% |
Free Cash Flow Margin | 23.47% | 31.43% | 13.38% | 11.46% | 9.82% | -6.31% |
EBITDA | 24.12 | 4.4 | 4.78 | 67.05 | 74.93 | 209.2 |
EBITDA Margin | 9.96% | 2.39% | 2.71% | 17.90% | 15.46% | 26.74% |
D&A For EBITDA | 27.98 | 28.46 | 28.54 | 38.36 | 39.13 | 35.9 |
EBIT | -3.86 | -24.06 | -23.76 | 28.68 | 35.8 | 173.3 |
EBIT Margin | -1.59% | -13.06% | -13.45% | 7.66% | 7.39% | 22.15% |
Effective Tax Rate | - | - | - | 65.79% | 20.64% | 20.44% |
Advertising Expenses | - | 0.12 | 0.1 | 0.77 | 4.19 | 7.02 |